TGFB1 and neoplasm: α-TGFβ monotherapy is consequently more efficacious (20% CR) than α-PD-1 monotherapy (< 3% CR), as it targets both Tregs and tumor cell EMT while also stimulating the effector arms of both the innate and adaptive immune systems.